logo-loader

Silence Therapeutics 'in a hot space with few competitors'

Published: 21:10 12 Jun 2018 AEST

Silence Therapeutics' (LON:SLN) executive chair Annalisa Jenkins sat down with Proactive's Andrew Scott to discuss her strategy for taking the drug developer forward and the 'exciting opportunities' in the RNAi space.

On what attracted Jenkins to join Silence, she says: ''The opportunity to be at a good company with a great platform, based in Europe and in a space that I think is at a really disruptive moment in time in terms of doing great things for patients''.

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

3 hours, 56 minutes ago